MYGN · Myriad Genetics Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$21.4M | Six months ended June 30 | — |
| Adjusted Free Cash Flow non-GAAP | -$30.8M | Six months ended June 30 | — |
| Adjusted Income (Loss) Per Share non-GAAP | -$0.34 | Six months ended June 30 | — |
| Adjusted Net Income (Loss) non-GAAP | -$31.6M | Six months ended June 30 | — |
| Adjusted Operating Cash Flow non-GAAP | -$21.1M | Six months ended June 30 | — |
| Adjusted operating cash outflow non-GAAP | $7.7M | Q2 2026 | — |
| Adjusted operating expenses non-GAAP | $150.5M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating Expenses 165.9M
-6.4M Acquisition - amortization of intangible assets
+0M Goodwill and long-lived asset impairment
-6.7M Equity compensation
+0M Real estate optimization
-2.3M Strategic realignment
+0M Other adjustments
= Adjusted Operating Expenses 150.5M
|
|||
| Cancer Care Continuum volume | 95K | Q2 2026 | — |
| Cash flow used in operations | $8.3M | Q2 2026 | — |
| Mental Health volume | 140K | Q2 2026 | — |
| Prenatal Health volume | 144K | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MYGN
this stock
Myriad Genetics Inc
|
$529.90M | -9.9% | -7.1% | — | 8.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$258.56B | +18.6% | +14.5% | 37.6 | 1.5% |
|
DHR
Danaher Corp /De/
|
$157.64B | -2.0% | +8.5% | 39.8 | 1.3% |
|
NTRA
Natera, Inc.
|
$58.51B | +77.2% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$48.56B | +27.1% | +6.4% | 33.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 20, 2026
- This year
- 17
On October 19, 2026, Myriad Genetics, Inc. agreed to sell its prenatal health business to Laboratory Corporation of America for $210 million in cash plus the value of inventory at closing.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MYGN | +35.8% | +37.8% | +18.4% | +28.5% | -9.9% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +36.9% | +38.4% | +10.3% | +27.7% | -22.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.